Key Takeaways Iovance posted a Q3 loss of $0.25 per share, beating expectations and improving from last year.Quarterly revenue rose 15$67.5M, led by strong Amtagvi demand despite a miss.Cost optimization efforts lifted gross margin to 43%, extending Iovance's cash runway into 2027.Iovance Biotherapeutics (IOVA) incurred a third-quarter 2025 loss of 25 cents per share, narrower than the Zacks Consensus Estimate of a loss of 29 cents. In the year-ago quarter, the company reported a loss of ...